← 返回前沿论文

CD68 作为消化系统癌症中的多组学预后生物标志物:与肿瘤浸润免疫细胞和免疫检查点的相关性

英文原题:CD68 as a multi-omic prognostic biomarker in digestive system cancers: correlations with tumor-infiltrating immune cells and immune checkpoints.

查看英文原题

CD68 as a multi-omic prognostic biomarker in digestive system cancers: correlations with tumor-infiltrating immune cells and immune checkpoints.

PubMed 2025/08/21(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

CD68 可能作为 COAD 和 STAD 中重要的预后生物标志物,并可能成为人类 DSC 诊断、预后和治疗靶向的有前景的候选分子。

研究思路结论见上方概要

CD68在促进吞噬作用中起着至关重要的作用。然而,其在人类消化系统癌症(DSC)中的表达水平、预后价值以及与肿瘤浸润免疫细胞(TIICs)或常见肿瘤免疫检查点(TICs)的相关性仍知之甚少。本研究旨在探讨CD68在DSC中的表达水平、预后意义和临床意义,以及其与六种TIICs和四种常见TICs的相关性。

我们通过在线数据库和免疫组化(IHC)对组织芯片(TMA)切片进行分析,检测了CD68 mRNA和蛋白表达,并将DSC肿瘤组织与癌旁正常组织进行比较。计算总生存期(OS)以评估CD68在DSC中的预后价值。此外,利用肿瘤免疫估计资源(TIMER)评估了CD68表达与六种TIIC(B细胞、CD4+ T细胞、CD8+ T细胞、巨噬细胞、NK细胞和癌症相关成纤维细胞)或四种常见TIC(PDCD1、CTLA4、IDO1和CD40)之间的相关性。

CD68 mRNA表达在食管癌(ESCA)和胃腺癌(STAD)组织中显著高于癌旁正常组织,但在结肠腺癌(COAD)、肝细胞癌(LIHC)和胰腺浸润性导管癌(PAAD)中较低。CD68蛋白表达在COAD中显著高于癌旁正常组织,但在ESCA、LIHC、PAAD和STAD中较低。CD68蛋白表达可作为COAD和STAD的预后标志物。此外,CD68表达与六种TIIC呈强正相关,与DSC中的四种TIC呈显著正相关。

展开英文摘要原文

CD68 plays a crucial role in promoting phagocytosis. However, its expression level, prognostic value and the correlations with tumor-infiltrating immune cells (TIICs) or common tumor immune checkpoints (TICs) in human digestive system cancers (DSC) remain poorly understood. This study aims to investigate the expression levels, prognostic significance, and clinical implications of CD68, as well as its correlations with six TIICs and four common TICs in DSC.

We analyzed CD68 mRNA and protein expression using online databases and immunohistochemistry (IHC) on tissue microarray (TMA) sections, comparing DSC tumor tissues with adjacent normal tissues. Overall survival (OS) was calculated to evaluate the prognostic value of CD68 in DSC. Additionally, correlations between CD68 expression and six TIICs (B cells, CD4+ T cells, CD8+ T cells, macrophages, NK cells, and cancer-associated fibroblasts) or four common TICs (PDCD1, CTLA4, IDO1, and CD40) were assessed using the Tumor Immune Estimation Resource (TIMER).

CD68 mRNA expression was significantly higher in esophageal carcinoma (ESCA) and stomach adenocarcinoma (STAD) tissues compared to adjacent normal tissues, but lower in colon adenocarcinoma (COAD), liver hepatocellular carcinoma (LIHC), and pancreas invasive ductal carcinoma (PAAD). Protein expression of CD68 was significantly higher in COAD than in adjacent normal tissues, but lower in ESCA, LIHC, PAAD, and STAD. CD68 protein expression served as a prognostic marker in COAD and STAD. Furthermore, CD68 expression showed strong positive correlations with the six TIICs and significant positive correlations with the four TICs in DSC.

CD68 may serve as an essential prognostic biomarker in COAD and STAD and could be a promising candidate for diagnostic, prognostic, and therapeutic targeting in human DSC.

论文信息

作者
Li H、Zhang H、Dai R、Zheng D、Zhao J、Jing H、Ma X、Zhang L
单位
Department of Digestion, Huaihe Hospital of Henan University, Kaifeng, China.China
期刊
Frontiers in immunology2025
原文标识
PubMed 40918116 · DOI 10.3389/fimmu.2025.1599677